Effects of Age on 1-Second Forced Expiratory Volume Response to Bronchodilation  by Liu, Ching-Lung et al.
International Journal of Gerontology | September 2009 | Vol 3 | No 3 149
Introduction 
Flow-volume spirometry is a reproducible and reliable
method for assessing lung function. The bronchodila-
tion test is used to detect reversible airways obstruc-
tion, considered to be important for diagnosing
asthma1,2. In clinical practice, the criterion for a signif-
icant spirometric bronchodilation response in adults is
recommended to be an increase in 1-second forced
expiratory volume (FEV1) of 12% and 200 mL from
baseline3,4.
The change in FEV1 (FEV1) in response to bron-
chodilation can be influenced by many factors, in-
cluding the bronchodilation medication, its mode of
delivery, and the type of spirometer used5,6. FEV1 has
been shown to be the best variable for determining the
response to bronchodilation in terms of statistical power
and reproducibility, but it is dependent on the baseline
FEV1 at the population level
6. Some previous reports
have documented smaller bronchodilation responses in
older people and an effect of sex on the response7,8. 
A low baseline ratio of FEV1 to forced vital capacity
(FVC), or FEV1:FVC ratio, also reflects airflow limitations
and is another determinant of the change in FEV1 in
response to bronchodilation9.
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SUMMARY
Background: The bronchodilation test is used to detect reversible airways obstruction, considered important
for diagnosing asthma. However, little is known about the effects of age on the bronchodilation response. The
aim of this study was to evaluate the effects of age on the bronchodilation response by determining changes in
the 1-second forced expiratory volume (FEV1) in a Chinese population.
Methods: All patients underwent pulmonary function testing to evaluate forced vital capacity, peak expiratory
flow, and FEV1. We assessed bronchodilation by measuring the change in FEV1 (FEV1) before and after inhala-
tion of 0.4 mg of fenoterol (two puffs) delivered by a metered-dose inhaler with a spacer.
Results: Of the 1,616 patients tested in the clinic, the 333 (21%) who had a positive bronchodilator test, defined
as FEV1 > 12% and 200 mL, were enrolled in the study. For this population, the FEV1 was +360.8 ± 138.6 mL
(mean ± standard deviation) or +21.0% ± 9.1%. In a multiple linear regression model, the absolute FEV1
(expressed in milliliters) was independently and negatively predicted by age (p < 0.001), and baseline peak expi-
ratory flow (p < 0.001), but positively predicted by height (p < 0.001).
Conclusion: Age was an important determinant for response to bronchodilation as determined by the absolute
change in FEV1. [International Journal of Gerontology 2009; 3(3): 149–155]
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Numerous studies on bronchodilation responses
have been published in patients with obstructive venti-
latory defects in selected or non-selected popula-
tions7–10. Some studies involved asthmatic population
samples with reversible obstructive airways, but the
concurrent changes in baseline lung function have not
been reported in aged populations7,8. Furthermore,
South Asian populations have a smaller FEV1 and FEV1
by volume and, therefore, are more likely to be classi-
fied as having an equivocal response. The aim of this
study was to evaluate the effects of age on the distri-
bution and range of the changes in FEV1 in response to
bronchodilation in a group of Chinese patients who
had a positive bronchodilator test.
Materials and Methods
Subjects and study design
A total of 1,616 patients underwent pulmonary function
measurements with bronchodilator testing in an out-
patient setting at a local teaching hospital in Taitung,
Taiwan, and a tertiary care medical center in Taipei
from January 2006 to December 2008. Patients were
excluded if they were < 18 years of age, had poor per-
formance on pulmonary function testing, or had a
peak expiratory flow (PEF) at < 40% of predicted.
All subjects who had a positive bronchodilator test
were included and categorized by age (< 30, 30–39,
40–49, 50–59, 60–69, and > 70 years of age).
Pulmonary function tests and bronchodilator test
Pulmonary function measurements were performed
according to the American Thoracic Society guide-
lines11,12. No bronchodilators, either β-adrenergic ago-
nists or theophylline, were administered within 8 hours
before the start of the study. All patients also under-
went spirometry and lung volume measurements
using either the nitrogen washout method (Vmax 22;
SensorMedics, Yorba Linda, CA, USA) at the Taitung
hospital, or a body plethysmograph (Vmax 22 and
Autobox 6200; SensorMedics) at the Taipei hospital.
Predicted and percent-predicted values were calcu-
lated for FEV1, FVC, and the FEV1:FVC ratio using the
reference values recommended by Knudson et al.13.
Bronchodilator reversibility tests were performed
using the largest FEV1 and FVC from the best of three
spirograms recorded on a single-breath bellows spirom-
eter11. All subjects then inhaled 0.4 mg (two puffs) of
fenoterol (Berotec; Boehringer Ingelheim, Ingelheim,
Germany) using a metered-dose inhaler (MDI) under
the guidance of a well-trained technician. Spirometry
was performed and repeated after a 15–20 minute
delay. A positive bronchodilator response was defined
as improvement of the FEV1 of > 12% and 200 mL over
baseline during a single testing session. Subjects with 
a positive bronchodilator response constituted our
study population.
Statistical analysis
All data are expressed as mean ± standard deviation.
Changes in FEV1 are expressed as absolute and percent
changes from baseline. Differences between groups
were analyzed as appropriate using the Pearson’s χ2
test for categorical variables. Bronchodilator response
variables (FEV1, expressed in milliliters and as per-
centage) were assessed using multiple logistic regres-
sion analysis. Analysis of variance, followed by Fisher’s
protected least significant difference post hoc test, was
used to compare differences in continuous variables
among the different age groups. A p value < 0.05 was
considered statistically significant. Differences between
groups were tabulated and analyzed using SPSS version
12.0 (SPSS Inc., Chicago, IL, USA).
Results
Population sample
A total of 1,616 patients underwent pulmonary func-
tion measurements with bronchodilator testing during
the study period. Of these, the response to bronchodila-
tors was positive in 333 individuals, who thus consti-
tuted the study population; of these, 114 (34%) were
elderly (age, 60–86 years).
For the population, the mean change in FEV1 was
+360.8 ± 138.6 mL or 21.0% ± 9.1%; the mean change
in FEV1 for men was +385.8 ± 149.2 mL or 21.5% ±
9.9% and that for women was +326.8 ± 117.2 mL or
20.7% ± 8.3% (Table 1). Men had a significantly greater
absolute FEV1 (p < 0.001), but the percentage of
FEV1 (%FEV1; p = 0.459) did not differ by sex 
(Table 1).
In a multiple linear regression model, the absolute
bronchodilator response (FEV1, expressed in milli-
liters) was independently and negatively predicted 
by age (p < 0.001), weight (p = 0.030) and baseline PEF
(p<0.001), but positively predicted by height (p<0.001)
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and body mass index (p = 0.020; Table 2). However, the
percentage changes in FEV1 were negatively predicted
only by the baseline FEV1:FVC ratio (p = 0.023) and PEF
(p < 0.001; Table 3).
Trends in lung function by age category
At the baseline pulmonary function test, the elderly
patients had significantly smaller FEV1:FVC ratio
(p < 0.001), forced expiratory flow between 25% and
75% of FVC (FEF25–75%) as a percentage of predicted
(p = 0.001), and PEF as a percentage of predicted
(p < 0.001) than the younger population (Table 4).
Trends in bronchodilation response by age
After inhalation of the bronchodilator, the FEV1 in-
creased significantly over baseline in both groups
(Table 4). The absolute bronchodilator response
(FEV1, expressed in milliliters) was independently
and negatively predicted by aging (p < 0.001; Table 4,
Figure 1). The elderly had an insignificantly greater
Table 1. Patient characteristics, baseline values, and bronchodilator responses in the study population of 333 participants
with a positive bronchodilator test*
Variables
Total Population sample
(n = 333) Men (n = 212) Women (n = 121) p
Age (yr) 53.3 ± 17.7 56.8 ± 17.9 47.2 ± 15.7 < 0.001
Height (cm) 162.0 ± 8.9 165.9 ± 7.9 155.2 ± 6.2 < 0.001
Weight (kg) 67.2 ± 13.4 69.7 ± 13.7 62.5 ± 11.2 < 0.001
BMI (kg/m2) 25.6 ± 4.8 25.3 ± 4.6 26.1 ± 5.1 0.145
FVC (% predicted) 81.8 ± 17.9 83.6 ± 20.0 78.8 ± 12.9 0.009
FEV1 (% predicted) 68.2 ± 16.6 68.7 ± 18.2 67.6 ± 13.3 0.508
FEV1/FVC 68.6 ± 10.7 66.5 ± 10.8 72.4 ± 9.7 < 0.001
FEF25–75% (% predicted) 43.9 ± 21.9 42.4 ± 21.6 47.0 ± 23.3 0.070
PEF (% predicted) 74.7 ± 19.6 71.6 ± 19.0 80.2 ± 19.9 < 0.001
Bronchodilation responses
FEV1 (mL) 360.8 ± 138.6 385.8 ± 149.2 326.8 ± 117.2 < 0.001
FEV1 (%) 21.0 ± 9.1 21.5 ± 9.9 20.7 ± 8.3 0.459
*Data are expressed as mean ± standard deviation. BMI = body mass index; FVC = forced vital capacity; FEV1 = 1-second forced expiratory vol-
ume; FEF25–75% = forced expiratory flow between 25% and 75% of forced vital capacity; PEF = peak expiratory flow; DFEV1 = change in 1-second
forced expiratory volume.
Table 2. Regression coefficients of bronchodilator response (change in 1-second forced expiratory volume, expressed in 
milliliters) for all participants (n = 333) in multiple regression models after adjustment for different variables
Variables Coefficient (SE) 95% CI p
Age (yr) –3.07 (0.49) –4.04 to –2.10 < 0.001
Height (cm) 13.95 (3.75) 6.57 to 21.34 < 0.001
Weight (kg) –9.40 (4.31) –17.88 to 0.93 0.030
BMI (kg/m2) 26.33 (11.26) 4.18 to 48.48 0.020
FVC (% predicted) 2.32 (1.97) –1.55 to 6.19 0.239
FEV1 (% predicted) –1.51 (2.41) –6.25 to 3.24 0.533
FEV1/FVC 0.29 (2.41) –4.45 to 5.03 0.896
FEF25–75% (% predicted) 0.65 (0.65) –0.63 to 1.93 0.319
PEF (% predicted) –1.11 (0.43) –1.94 to –0.27 < 0.001
SE = standard error; CI = confidence interval; BMI = body mass index; FVC = forced vital capacity; FEV1 = 1-second forced expiratory volume;
FEF25–75% = forced expiratory flow between 25% and 75% of forced vital capacity; PEF = peak expiratory flow.
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bronchodilation response in %FEV1 (p = 0.052) com-
pared with the young population (Table 4, Figure 2).
Discussion
This study demonstrates that lung function and bron-
chodilation response were correlated with aging. The
elderly were short in height and had a significantly
smaller FEV1:FVC ratio, FEF25–75%, and PEF as a percent-
age of predicted than the young population. The bron-
chodilator response to inhaled fenoterol in the elderly
was significantly lower in volume of FEV1 but slightly
increased in %FEV1, compared with the young popu-
lation. This suggests that age is an important deter-
minant for absolute volume of FEV1 response to
bronchodilation.
Some investigators have suggested that spirometry,
and particularly assessment of the bronchodilator
response, is not uniformly sensitive for the diagnosis
of asthma, with sensitivities reportedly ranging from
82–93%, depending on the criteria used for a positive
response14,15. Our data suggests that some of the vari-
ability in response to inhaled β2-agonists can be
attributed to age, height, sex, and baseline FVC. So, for
example, we found that younger, taller patients who
had a larger baseline FVC had a relatively larger
improvement in the volume of FEV1, but a smaller
percentage improvement. Similarly, short, older Asian
women in our study had a smaller FEV1 by volume
and, therefore, were more likely to be classified as hav-
ing an equivocal response. Asthma cannot be defini-
tively excluded in such cases.
We found that preexisting airflow limitation in terms
of decreased FEV1:FVC ratio and lung volume was the
strongest determinant for bronchodilation responses in
the reversible obstructive airway population. Although 
a larger absolute bronchodilation response was found
in men than in women, this phenomenon can be
explained by the more frequent findings of airflow
limitation (i.e., reduced FEV1:FVC ratio) and a larger
FVC in men16,17. In our participants, we observed a sig-
nificant negative correlation with age more clearly
with the absolute change in FEV1 and less so with the
relative change in FEV1. This can be partially attributed
to the aging-related reduction in FEV1:FVC ratio and
smaller lung volumes found in persons in older age
groups16,17. A weak negative correlation of age with
change in FEV1 might also be explained by the dimin-
ished coordination and greater fatigue common in
elderly patients, resulting more frequently in the
decreasing FEV1 found in bronchodilation test results.
PEF is a measure of maximal expiratory flow that is
used to assess qualitative and quantitative effort in
spirometry maneuvers18–20. FEV1 is a measurement of
volume in the first second of a spirometry maneuver2,4.
Both of these measurements have played an impor-
tant role in the identification and management of differ-
ent severities of asthma. FEV1 is commonly assumed to
be partly dependent on PEF on the basis of a high corre-
lation between PEF and FEV1
21,22. Hence, the maximal
expiratory work was related to the highest PEF, but the
highest PEF was not associated with the largest FEV1
23.
Previous studies have reported only a weak correlation
between PEF variability and FEV1 variability
22,23. In our
data, there is a trend toward lower PEF and smaller FEV1
Table 3. Regression coefficients of bronchodilator response (change in 1-second forced expiratory volume, expressed as 
percentage) for all participants (n = 333) in multiple regression models after adjustment for different variables
Variables Coefficient (SE) 95% CI p
Age (yr) –0.03 (0.03) –0.09 to 0.04 0.399
Height (cm) 0.23 (0.25) –0.26 to 0.71 0.363
Weight (kg) –0.46 (0.28) –1.02 to 0.10 0.106
BMI (kg/m2) 1.36 (0.74) –0.10 to 2.81 0.068
FVC (% predicted) –0.13 (0.13) –0.39 to 0.12 0.300
FEV1 (% predicted) –0.02 (0.16) –0.33 to 0.29 0.889
FEV1/FVC –0.36 (0.16) –0.67 to –0.05 0.023
FEF25–75% (% predicted) 0.05 (0.04) –0.04 to 0.13 0.255
PEF (% predicted) –0.11 (0.03) –0.17 to –0.06 < 0.001
SE = standard error; CI = confidence interval; BMI = body mass index; FVC = forced vital capacity; FEV1 = 1-second forced expiratory volume;
FEF25–75% = forced expiratory flow between 25% and 75% of forced vital capacity; PEF = peak expiratory flow.
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in the elderly participants. However, after bronchodila-
tion, the percentages of FEV1 or PEF (data not shown)
were not correlated with aging. PEF is considered as an
expiratory effort, and it seemed to be negatively corre-
lated with aging. On the other hand, the percentage of
PEF indicated a reversibility of obstructive airway, and
it seemed not to be related to aging.
Inhaled β-adrenergic bronchodilators are corner-
stones in the management of asthma2. MDI delivery
of these drugs has the advantage of convenience, ease
of administration, and rapid onset of action. However,
MDIs are not without their shortcomings. Many pa-
tients, particularly the very young and elderly, have dif-
ficulty coordinating inhaler actuation with inspiratory
effort24,25. Our research technicians were careful to
ensure that the study participants were using the MDI
correctly; therefore, caution must be used in generalizing
the results to patients who might have difficulty using
the correct technique.
A limitation of this study was variation in the time
between inhalation and the second spirometry. Our
second measurements were generally made 15–20
minutes after inhalation. The variations in time interval
might affect the values obtained for bronchodilation
response. However, we believe our data are robust
enough to demonstrate the essentially equivalent lung
function and bronchodilation responses with aging.
In conclusion, this study showed that age is an
important determinant for lung function and bron-
chodilation response. The elderly were shorter in height
and had a significantly smaller FEV1:FVC ratio and lower
PEF as a percentage of predicted values. The absolute
bronchodilator response (FEV1, expressed in millilters)
was independently and negatively predicted by aging.
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